Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 Nov;30(5):701–704. doi: 10.1128/aac.30.5.701

Penetration of aztreonam into cerebrospinal fluid and brain of noninfected rabbits and rabbits with experimental meningitis caused by Pseudomonas aeruginosa.

L J Strausbaugh, C R Bodem, P R Laun
PMCID: PMC176517  PMID: 3099641

Abstract

This study examined the penetration of aztreonam into the cerebrospinal fluid (CSF) and brain in noninfected rabbits and rabbits with experimental meningitis caused by Pseudomonas aeruginosa. Animals received either 600 or 1,200 mg of aztreonam administered intravenously over 6 h. Aztreonam did not readily enter the CSF in the absence of meningitis. In noninfected animals, mean concentrations in the CSF ranged from 1.1 to 3.0 micrograms/ml with the 600-mg dose and from 2.3 to 4.7 micrograms/ml with the 1,200-mg dose. In contrast, mean concentrations of aztreonam in the CSF were significantly higher (P less than 0.01) at each sampling time in rabbits with experimental meningitis caused by P. aeruginosa. They ranged from 10.2 to 14.6 micrograms/ml with the 600-mg dose and from 29 to 40 micrograms/ml with the 1,200-mg dose. Although concentrations in the brain measured at 6 h tended to be higher in infected rabbits, this difference was not statistically significant. Aztreonam therapy produced a substantial decline in CSF bacterium counts over 6 h: mean CSF counts decreased 2.4 log10 CFU/ml in the 600-mg dose group and 3.0 log10 CFU/ml in the 1,200-mg dose group. The results of this study suggest that aztreonam may be useful in the therapy of meningitis caused by P. aeruginosa.

Full text

PDF
701

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L., Thornsberry C., Jones R. N., Gavan T. L. Aztreonam: antibacterial activity, beta-lactamase stability, and interpretive standards and quality control guidelines for disk-diffusion susceptibility tests. Rev Infect Dis. 1985 Nov-Dec;7 (Suppl 4):S594–S604. doi: 10.1093/clinids/7.supplement_4.s594. [DOI] [PubMed] [Google Scholar]
  2. Beam T. R., Jr, Allen J. C. Blood, brain, and cerebrospinal fluid concentrations of several antibiotics in rabbits with intact and inflamed meninges. Antimicrob Agents Chemother. 1977 Dec;12(6):710–716. doi: 10.1128/aac.12.6.710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cherubin C. E., Marr J. S., Sierra M. F., Becker S. Listeria and gram-negative bacillary meningitis in New York City, 1972-1979. Frequent causes of meningitis in adults. Am J Med. 1981 Aug;71(2):199–209. doi: 10.1016/0002-9343(81)90106-6. [DOI] [PubMed] [Google Scholar]
  4. Dacey R. G., Sande M. A. Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives. Antimicrob Agents Chemother. 1974 Oct;6(4):437–441. doi: 10.1128/aac.6.4.437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Duma R. J., Berry A. J., Smith S. M., Baggett J. W., Swabb E. A., Platt T. B. Penetration of aztreonam into cerebrospinal fluid of patients with and without inflamed meninges. Antimicrob Agents Chemother. 1984 Nov;26(5):730–733. doi: 10.1128/aac.26.5.730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hodges G. R., Perkins R. L. Hospital-associated bacterial meningitis. Am J Med Sci. 1976 May-Jun;271(3):335–341. doi: 10.1097/00000441-197605000-00009. [DOI] [PubMed] [Google Scholar]
  7. McCracken G. H., Jr, Sakata Y., Olsen K. D. Aztreonam therapy in experimental meningitis due to Haemophilus influenzae type b and Escherichia coli K1. Antimicrob Agents Chemother. 1985 Apr;27(4):655–656. doi: 10.1128/aac.27.4.655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Mihindu J. C., Scheld W. M., Bolton N. D., Spyker D. A., Swabb E. A., Bolton W. K. Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction. Antimicrob Agents Chemother. 1983 Aug;24(2):252–261. doi: 10.1128/aac.24.2.252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Scheld W. M., Brodeur J. P., Foresman P. A., Gratz J. C., Rodeheaver G. T. Comparative evaluation of aztreonam in therapy for experimental bacterial meningitis and cerebritis. Rev Infect Dis. 1985 Nov-Dec;7 (Suppl 4):S635–S647. doi: 10.1093/clinids/7.supplement_4.s635. [DOI] [PubMed] [Google Scholar]
  10. Scheld W. M., Brodeur J. P., Gratz J. C., Foresman P., Rodeheaver G. Evaluation of aztreonam in experimental bacterial meningitis and cerebritis. Antimicrob Agents Chemother. 1983 Nov;24(5):682–688. doi: 10.1128/aac.24.5.682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Scheld W. M., Brodeur J. P., Keeley J. M. Evaluation of mezlocillin in discriminative animal models of infection. J Antimicrob Chemother. 1982 Jan;9 (Suppl A):51–64. doi: 10.1093/jac/9.suppl_a.51. [DOI] [PubMed] [Google Scholar]
  12. Scheld W. M., Brodeur J. P., Keeley J. M., Field M. R., Kelly W. J., 4th, Long W. J., Jr, Zak O. Evaluation of azlocillin in vitro and in discriminative animal models of infection. J Antimicrob Chemother. 1983 May;11 (Suppl B):51–68. doi: 10.1093/jac/11.suppl_b.51. [DOI] [PubMed] [Google Scholar]
  13. Swabb E. A., Leitz M. A., Pilkiewicz F. G., Sugerman A. A. Pharmacokinetics of the monobactam SQ 26,776 after single intravenous doses in healthy subjects. J Antimicrob Chemother. 1981 Dec;8 (Suppl E):131–140. doi: 10.1093/jac/8.suppl_e.131. [DOI] [PubMed] [Google Scholar]
  14. Sykes R. B., Bonner D. P., Bush K., Georgopapadakou N. H. Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria. Antimicrob Agents Chemother. 1982 Jan;21(1):85–92. doi: 10.1128/aac.21.1.85. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES